Lisa A. Jackson, MD, MPH

Jackson_Lisa_A__205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine  safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

Recent publications

Appiah GD, Chung JR, Flannery B, Havers F, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, Jackson LA, Jackson ML, McLean HQ, Belongia EA, Fry AM. Hospitalization following outpatient medical care for influenza: US Influenza Vaccine Effectiveness Network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 Mar;13(2):133-137. doi: 10.1111/irv.12616. Epub 2018 Dec 19. PubMed

Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 Nov 9. pii: S0264-410X(18)31490-7. doi: 10.1016/j.vaccine.2018.10.093. [Epub ahead of print]. PubMed

Munoz FM, Jackson LA, Swamy GK, Edwards KM, Frey SE, Stephens I, Ault K, Winokur P, Petrie CR, Wolff M, Patel SM, Keitel WA. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 Nov 8. pii: S0264-410X(18)31475-0. doi: 10.1016/j.vaccine.2018.10.088. [Epub ahead of print]. PubMed

Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, Fry AM, Flannery B. Influenza vaccine effectiveness and statin use among adults in the United States, 2011-2017. Clin Infect Dis. 2019 May 2;68(10):1616-1622. doi: 10.1093/cid/ciy780. PubMed

Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Rolfes MA, Spencer S, Fry AM. Influenza vaccine effectiveness in the United States during the 2016-2017 season. Clin Infect Dis. 2019 May 17;68(11):1798-1806. doi: 10.1093/cid/ciy775. PubMed

Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. LID - S0264-410X(18)31214-3 [pii] LID - 10.1016/j.vaccine.2018.08.074 [doi] Vaccine. 2018 Sep 4. pii: S0264-410X(18)31214-3. doi: 10.1016/j.vaccine.2018.08.074 [Epub ahead of print] PubMed

Brady RC, Jackson LA, Frey SE, Shane AL, Walter EB, Swamy GK, Schlaudecker EP, Szefer E, Wolff M, McNeal MM, Bernstein DI, Steinhoff MC. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. Vaccine. 2018;36(31):4663-4671. doi: 10.1016/j.vaccine.2018.06.036. Epub 2018 Jun 28. PubMed

Jackson ML, Yu O, Nelson JC, Nordin JD, Tartof SY, Klein NP, Donahue JG, Irving SA, Glanz JM, McNeil MM, Jackson LA. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3. PubMed

Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM. Outpatient antibiotic prescribing for acute respiratory infections during influenza seasons. JAMA Netw Open. 2018 Jun 1;1(2):e180243. doi: 10.1001/jamanetworkopen.2018.0243. PubMed

Tseng HF, Sy L, Qian L, Liu IA, Mercado C, Lewin B, Tartof SY, Nelson JC, Jackson LA, Daley MF, Weintraub E, Klein NP, Belongia E, Liles EG, Jacobsen SJ. Pneumococcal conjugate vaccine safety in elderly adults. Open Forum Infectious Diseases, Volume 5, Issue 6, 1 June 2018, ofy100, https://doi.org/10.1093/ofid/ofy100.

 

Volunteers needed

Vaccine-trial-vaccine-boosters_1col.jpg

COVID-19 booster trial seeks unvaccinated volunteers

KPWHRI to access the benefits of mixing different vaccine types in NIAID-sponsored study.

1-year anniversary

Covid-19-vaccine-KPWHRI-trial_1col_.jpg

Looking back: Our COVID-19 vaccine trial at 1 year

Dr. Rita Mangione-Smith reflects on the year since KPWHRI launched the world's first clinical trial for a COVID-19 vaccine.

Phase 1 trial

News_-_Lisa_Jackson_and_Michael_Witter_-_1_column.jpg

‘Fighting back’ against COVID-19: Remembering a historic trial

Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.

KPWHRI In the Media

Seattle-based clinical trial tweaks mRNA vaccines to fight COVID variants

Seattle NPR affiliate KUOW-FM, April 8, 2021

1st vaccine shot

News_-_covid19_-_First_vaccine-1_column.jpg

COVID-19 vaccine trial volunteer on the shot heard 'round the world

On March 16, 2020, Jennifer Haller became the first person to be injected with a COVID-19 vaccine in a clinical trial.